Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy Combined With Toripalimab for Triple-negative Breast Cancer
NCT06682195Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Pathologic Complete Response at 2 years and Adverse Events at 2 years. Started Oct 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06682195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682195.